LFCR Earnings Prediction
The chart below shows how LFCR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LFCR sees a +0.46% change in stock price 10 days leading up to the earnings, and a -3.09% change 10 days following the report. On the earnings day itself, the stock moves by -2.71%. This data can give you a slight idea of what to expect for the next quarter's release.
LFCR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
32.56M
8.01%
31.81%
Gross Margin
34.04%
3.09%
56.08%
Operating Margin
-4.78%
-208.88%
-84.26%
Net Margin
-20.18%
-142.72%
-69.28%
EPS
-0.25
-164.10%
-52.83%
No Data Available
LFCR Earnings Analysis
Lifecore Biomedical Inc Corporation (LFCR.O) Earnings Conference Call
Positive
Revenue Increase Analysis: Revenues for the three months ended November 24, 2024 were $32.6 million, an increase of 8% compared to $30.2 million for the comparable prior year.
Gross Profit Increase: Gross profit for the three months ended November 24, 2024 was $11.1 million compared to $10 million for the same period last year, reflecting a $1.1 million increase.
Adjusted EBITDA Increase: Adjusted EBITDA for the three months ended November 24, 2024 was $6.5 million, an increase of $1.1 million compared to $5.4 million in the prior year period.
Revenue Increase Analysis: Revenues for the six months ended November 24, 2024 were $57.3 million, an increase of 5% compared to $54.7 million for the comparable prior year.
PIPE Offering Success: The company successfully closed a previously announced $24.3 million PIPE offering, significantly improving liquidity and allowing management to focus on growth opportunities.
Negative
Revenue Increase Analysis: Revenue for the three months ended November 24, 2024, was $32.6 million, an increase of 8% compared to $30.2 million for the comparable prior year, indicating a slower growth rate than expected.
Gross Profit Improvement: Gross profit for the three months ended November 24, 2024, was $11.1 million compared to $10 million for the same period last year, reflecting only a modest improvement in profitability despite increased revenues.
Rising Operational Costs: Selling, general, and administrative expenses for the three months ended November 24, 2024, were $11.1 million compared to $9.3 million for the same period last year, indicating rising operational costs that could pressure margins.
Net Loss Decline: The company recorded a net loss of $6.6 million and $0.25 of loss per diluted share compared to net income of $14.2 million and $0.39 of income per diluted share for the same period last year, showing a significant decline in profitability.
Adjusted EBITDA Increase: Adjusted EBITDA for the three months ended November 24, 2024, was $6.5 million, an increase of $1.1 million compared to $5.4 million in the prior year period, but still below expectations for sustainable growth.
LFCR FAQs
How does LFCR typically perform around its earnings report dates?
Is Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LFCR Earning Call Sentiment
Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Transcript
1.0x
00:00
00:00
LFCR.O
1.21%Positive
The earnings call summary highlights strong financial performance, with a 15% revenue increase and improved margins. The optimistic guidance of a 10% revenue increase for FY25 and a share buyback program further bolster a positive outlook. Despite some concerns about supply chain challenges and competitive pressures, management's proactive measures to address these issues and the upcoming new product launches contribute to a positive sentiment. The Q&A session did not significantly alter the positive view, as management expressed confidence in growth prospects.
